The stigma of patients with chronic insomnia: a clinical study.
BMC Psychiatry
Department of Neurology (Sleep Disorders), The Affiliated Chaohu Hospital of Anhui Medical University, Hefei, 238000, Chaohu, China.
Published: July 2022
Background: The objective of this study was to explore the stigma and related influencing factors in individuals with chronic insomnia disorder (CID).
Methods: A total of 70 CID patients and 70 healthy controls (CON) were enrolled in the study. All subjects completed the assessments of sleep, emotion, and cognition. Their stigma and life quality were measured using the Chronic Stigma Scale and the 36-Item Short-Form Health Survey (SF-36).
Results: The ratio of individuals with stigma was significantly different between CID and CON groups (C = 35.6, p < 0.001). Compared with the CON group, the CID group had higher scores for total stigma (U = 662.0, p < 0.001), internalized stigma (U = 593.0, p < 0.001), enacted stigma (U = 1568.0, p < 0.001), PSQI (U = 2485.0, p < 0.001) and HAMD-17 (U = 69.5, p < 0.001) as well as lower scores for MoCA-C (U = 3997.5, p < 0.001) and most items of SF-36. Partial correlation analysis showed that different items of the Chronic Stigma Scale were positively correlated with illness duration, PSQI and HAMD-17 scores, while negatively correlated with one or more items of the SF-36. Multivariate regression analysis showed that illness duration and the Mental Health domain of the SF-36 were independent risk factors for one or more items of stigma in CID patients.
Conclusion: Patients with CID have an increased risk of stigma. Moreover, illness duration and Mental Health may be primary factors related to stigma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254637 | PMC |
| http://dx.doi.org/10.1186/s12888-022-04091-y | DOI Listing |
Similar Publications
Digital Cognitive Behavioral Therapy-Based Treatment for Insomnia, Nightmares, and Posttraumatic Stress Disorder Symptoms in Survivors of Wildfires: Pilot Randomized Feasibility Trial.
JMIR Hum Factors
March 2025
School of Health and Biomedical Sciences, Royal Melbourne Institute of Technology University, Melbourne, Australia.
Background: Symptoms of insomnia, nightmares, and trauma are highly prevalent. However, there are significant barriers to accessing evidence-based treatments for these conditions, leading to poor mental health outcomes.
Objective: This pilot trial evaluated the feasibility of a 4-week, digital self-paced intervention combining cognitive behavioral therapy for insomnia and exposure, relaxation, and rescripting therapy for nightmares in survivors of wildfires from Australia, Canada, and the United States.
Determinants of treatment response to cognitive behavioral therapy in veterans presenting with comorbid insomnia and sleep apnea.
Sleep Breath
March 2025
Sleep Disorders Research Center, VA Western New York Healthcare System, Buffalo, NY, USA.
Purpose: Although cognitive behavioral therapy for insomnia (CBT-I) is considered the preferred treatment for insomnia in patients with comorbid insomnia and obstructive sleep apnea (COMISA), the remission rate with CBT-I is generally considered lower than in insomnia-only populations. There is also a sizable variability in individual treatment responses. Due to the limited availability of CBT-I, we sought to identify specific clinical attributes that predict benefit from Brief Behavioral Therapy for Insomnia (BBTI)-an adaptation of CBT-I-in patients with COMISA.
View Article and Find Full Text PDFComparison of diaphragmatic breathing relaxation training and cognitive-behavioral therapy on sleep quality in the elderly: a randomized clinical trial.
Sleep Breath
March 2025
Ali Ibn Abi Taleb Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Objective: To examine the effects of diaphragm breathing relaxation training and cognitive-behavioral therapy on sleep quality in the elderly.
Methods: In this three-arm randomized clinical trial, 99 older patients with a primary diagnosis of insomnia were randomly divided into two intervention groups (n = 33) and a control group (n = 33). The study design was a parallel group trial with an allocation ratio of 1:1.
Treatments for enhancing sleep quality in fibromyalgia: a systematic review and meta-analysis.
Rheumatology (Oxford)
March 2025
Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Objectives: Sleep disturbance is a key symptom of fibromyalgia and a risk factor for chronic widespread pain. This systematic review and meta-analysis aims to assess the effectiveness of pharmacological treatments and cognitive behavioural therapy (CBT) in improving sleep quality in fibromyalgia patients.
Methods: A systematic search of PubMed, MEDLINE, Embase, Cochrane CENTRAL, and CINAHL was conducted for randomized controlled trials (RCTs) published up to April 2023.
A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia.
J Sleep Res
March 2025
Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
This double-blind, placebo-controlled, two-way crossover trial evaluated the efficacy and safety of daridorexant in patients with chronic insomnia and comorbid nocturia. In total, 60 patients aged ≥55 years with insomnia complaints for ≥3 months, Insomnia Severity Index (ISI) ≥13 and ≥3 voids/night for ≥1 month were randomised (1:1) to daridorexant 50 mg/placebo for 4 weeks followed by crossover after a 14-21-day washout period. The primary endpoint was change from baseline to Week (W) 4 in self-reported total sleep time (sTST).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.